title: Effect of the aromatase inhibitor CGS-16949A on pregnancy and secretion of progesterone, estradiol-17beta, prostaglandins E and F2alpha (PGE; PGF2alpha) and pregnancy specific protein B (PSPB) in 90-day ovariectomized pregnant ewes.
abstract: The aromatase inhibitor CGS-16949A was used to determine whether CGS-16949A altered secretion of progesterone, estradiol-17beta, PGE (PGE1 + PGE2), PGF2alpha and PSPB. Ninety day pregnant ewes were ovariectomized and received vehicle, PGF2alpha, CGS-16949A or PGF2alpha+CGS-16949A. None of the ewes treated with PGF2alpha, CGS-16949A or PGF2alpha+CGS-16949A aborted (P > or = 0.05) during the 108-h experimental period. Treatment with CGS-16949A lowered (P < or = 0.05) progesterone in jugular venous plasma but concentrations of progesterone were not affected (P > or = 0.05) by treatment with PGF2alpha. Concentrations of estradiol-17beta and PSPB in jugular venous plasma and PGE in inferior vena cava plasma were decreased (P < or = 0.05) by treatment with CGS-16949A. Concentrations of PGF2alpha in inferior vena cava plasma were not affected (P > or = 0.05) by treatment with CGS-16949A. Decreases in estradiol-17beta occurred before decreases in PSPB, which was then followed by decreases in PGE (P < or = 0.05). It is concluded that these data support the hypothesis that estradiol-17beta regulates placental secretion of PSPB; PSPB regulates placental secretion of PGE; and PGE regulates placental secretion of progesterone during mid-pregnancy in ewes.
authors.affiliation: Department of Human Nutrition, Food, and Animal Sciences, University of Hawaii, Honolulu 96822, USA. weems@hawaii.edu
authors.forename: Y S
authors.initials: YS
authors.lastname: Weems
authors.forename: P J
authors.initials: PJ
authors.lastname: Bridges
authors.forename: B R
authors.initials: BR
authors.lastname: LeaMaster
authors.forename: R G
authors.initials: RG
authors.lastname: Sasser
authors.forename: L
authors.initials: L
authors.lastname: Ching
authors.forename: C W
authors.initials: CW
authors.lastname: Weems
mesh_terms: D000818:Animals; D047072:Aromatase Inhibitors; D016282:Aspartic Acid Endopeptidases / Q000378:metabolism*; D015237:Dinoprost / Q000378:metabolism*; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D004958:Estradiol / Q000378:metabolism*; D004965:Estrogen Antagonists / Q000494:pharmacology; D017316:Fadrozole / Q000494:pharmacology*; D005260:Female; D010052:Ovariectomy; D011247:Pregnancy; D011257:Pregnancy Proteins / Q000378:metabolism*; D011374:Progesterone / Q000378:metabolism*; D011458:Prostaglandins E / Q000378:metabolism*; D012756:Sheep
chemical_list: D047072:Aromatase Inhibitors; D004791:Enzyme Inhibitors; D004965:Estrogen Antagonists; D011257:Pregnancy Proteins; D011458:Prostaglandins E; D011374:Progesterone; D004958:Estradiol; D015237:Dinoprost; D016282:Aspartic Acid Endopeptidases; C094766:pregnancy-associated glycoprotein 1; D017316:Fadrozole